PCVX 8-K SEC Filing Analysis

Final — all horizons settled through T+60d ⚠ clustered

PCVX ▼ -25.17% at T+60d

NEUTRAL call ✗ call lost -25.17% · α vs SPY -32.13% · entry $63.04 → $47.17

Last close $46.33 (close Jun 8) · -26.51% from $63.04 entry

Entry anchored
Feb 24, 03:59 PM ET
via Databento tick

T+1d

-4.82%

call -4.82% · α -4.28%

$60.00

settled 4mo ago

T+5d

-4.62%

call -4.62% · α -3.52%

$60.13

settled 3mo ago

T+20d

-11.31%

call -11.31% · α -6.07%

$55.91

settled 3mo ago

T+60d

-25.17%

call -25.17% · α -32.13%

$47.17

settled 21d ago

Price Chart

Loading chart...

Executive Summary

Vaxcyte reported its 2025 financial results, showing increased R&D and operating expenses leading to a larger net loss, while maintaining a strong cash position of $2.44 billion. The company highlighted clinical progress on its VAX-31 vaccine program, including initiation of three Phase 3 trials and completion of enrollment in an infant Phase 2 study, along with a recent $632.5 million equity offering that strengthens its balance sheet.

Key Financial Metrics

EPS

$-5.63

Actionable Insight

Monitor upcoming clinical data readouts: topline data from OPUS-1 expected in Q4 2026, and OPUS-2/OPUS-3 data expected in first half of 2027. The strong cash position provides runway for clinical development, but continued losses are expected until potential commercialization.

Key Facts

Cash, cash equivalents and investments were $2.44 billion as of December 31, 2025, down from $3.13 billion in 2024
Completed $632.5 million equity offering in February 2026
Net loss was $766.6 million for 2025, compared to $463.9 million in 2024
Research and development expenses were $794.3 million for 2025, up from $476.6 million in 2024
Initiated three Phase 3 trials for VAX-31 (OPUS-1, OPUS-2, OPUS-3)
Completed enrollment in VAX-31 infant Phase 2 dose-finding study with 900 infants
No revenue or earnings guidance provided

Financial Impact

Increased R&D spending by $317.7 million year-over-year to $794.3 million, resulting in net loss expanding by $302.7 million to $766.6 million

cashnet lossr&d expenses

Risk Factors

Clinical trial setbacks could impact valuation
Continued significant cash burn from R&D investments
No revenue generation expected for several years as company remains pre-commercial

Market Snapshot

Exchange

Nasdaq

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001649094-26-000005
Document: pcvx-20260224.htm	0001649094-26-000005
Document: 0001649094-26-000005-index-headers.html	0001649094-26-000005
Document: 0001649094-26-000005-index.html	0001649094-26-000005
Document: 0001649094-26-000005.txt	0001649094-26-000005

7 reports for PCVX

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for PCVX — sortable, filterable
	Type				Now
Jun 2, 2026 7d ago	Press Release NEUTRAL ★ 4/10	$46.93 $48.76	▲ +3.90%	▲ +3.49%	$46.33 (−1.28%)
May 6, 2026 4w ago	8-K BEARISH ★ 7/10	$51.48 $53.01	▼ −2.97%	▼ −2.14%	$46.33 (+10.00%)
Apr 23, 2026 6w ago	DEFA14A NEUTRAL ★ 3/10	$59.49 $59.72	▲ +0.39%	▲ +0.22%	$46.33 (−22.12%)
Apr 1, 2026 10w ago	Insider Cluster NEUTRAL ★ 3/10	$58.50 $58.38	▼ −0.21%	▼ −0.28%	$46.33 (−20.80%)
Mar 23, 2026 11w ago	Press Release NEUTRAL ★ 4/10	$55.94 $54.67	▼ −2.27%	▼ −1.91%	$46.33 (−17.18%)
Feb 24, 2026 15w ago	8-K NEUTRAL ★ 4/10	$63.04 $60.00	▼ −4.82%	▼ −4.28%	$46.33 (−26.51%)
Feb 24, 2026 15w ago	8-K NEUTRAL ★ 5/10	$63.04 $60.00	▼ −4.82%	▼ −4.28%	$46.33 (−26.51%)

US Market Status

Market Closed — Opens in 7h 15m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access